[Skip to Content]
[Skip to Content Landing]
February 3, 1999

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial

Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim Co-EditorIndividualAuthor

JAMA. 1999;281(5):414-419. doi:10.1001/jama.281.5.414

To the Editor: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) provides further evidence on the benefit of statin treatment for primary prevention of coronary heart disease (CHD).1 The relative risk (RR) reduction for nonfatal myocardial infarction (MI) and CHD death (42%) was broadly similar to that in previous statin trials. However, the population studied had a much lower risk of CHD than those enrolled in previous studies, with a rate of nonfatal MI and CHD death in the placebo group of 0.6% per year. As a result, the absolute risk reduction for these events was much smaller than in previous trials, at around 0.2% per year. This corresponds to a number needed to treat (NNT) of 86 to prevent 1 CHD event over 5 years.